Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Personalized Marker-driven Early Switch to Aflibercept in Patients With Metastatic Colorectal Cancer (PERMAD-Trial) - a Multicenter, Multinational, Two Part, Phase II Trial

NCT02331927 is registered in ClinicalTrials.gov with University of Ulm as lead sponsor.

NCT NCT02331927
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02331927 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Personalized Marker-driven Early Switch to Aflibercept in Patients With Metastatic Colorectal Cancer (PERMAD-Trial) - a Multicenter, Multinational, Two Part, Phase II Trial
Lead sponsor
University of Ulm
Phase
Phase 2
Overall status
Unknown status
Start date
March 31, 2015
Completion date
March 31, 2021
Enrollment
150 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic colorectal cancer